Development and maintenance of chronic pain is associated with structural and functional brain reorganization. However, few studies have explored the impact of drug treatments on such changes. The extent to which long-term analgesia is related to brain adaptations and its effects on the reversibility of brain reorganization remain unclear. In a randomized placebo-controlled clinical trial, we contrasted pain relief (3-month treatment period), and anatomical (gray matter density [GMD], assessed by voxel-based morphometry) and functional connectivity (resting state fMRI nodal degree count [DC]) adaptations, in 39 knee osteoarthritis (OA) patients (22 females), randomized to duloxetine (DLX, 60 mg once daily) or placebo. Pain relief was equivalent between treatment types. However, distinct circuitry (GMD and DC) could explain pain relief in each group: up to 85% of variance for placebo analgesia and 49% of variance for DLX analgesia. No behavioral measures (collected at entry into the study) could independently explain observed analgesia. Identified circuitry were outside of nociceptive circuitry and minimally overlapped with OA-abnormal or placebo response predictive brain regions. Mediation analysis revealed that changes in GMD and DC can influence each other across remote brain regions to explain observed analgesia. Therefore, we can conclude that distinct brain mechanisms underlie DLX and placebo analgesia in OA. The results demonstrate that even in the absence of differences in subjective pain relief, pharmacological treatments can be differentiated from placebo based on objective brain biomarkers. This is a crucial step to untangling mechanisms and advancing personalized therapy approaches for chronic pain. wileyonlinelibrary.com/journal/hbm Hum Brain Mapp.
| I N TR ODU C TI ON
Dissemination of modern pharmacotherapies is based on clinical trials where the treatment shows superior efficacy in comparison to a placebo. In pain studies especially, such randomized controlled trials (RCTs) commonly show a large placebo response. When the active treatment does not prove superior to the placebo, the common assumption is that the two arms of the study have equivalent effects on the participants. Then, the trial is announced to be a failure and the treatment abandoned. However, since brain imaging may provide objective markers of the effects of such treatments on the organism, it enables a more nuanced and biologically based interpretation of RCT outcomes, where active treatment and placebo might be differentiated at the brain circuit level. Here we test this general concept by studying brain anatomical and functional changes accompanying active drug (duloxetine)-in contrast to placebo-treatment in an RCT performed in osteoarthritis (OA) patients.
OA pain is unique in numerous ways when compared to other chronic painful conditions (Felson, 2005) . These differences include the initial peripheral event located in the affected joint, the spinal cord plasticity, and condition-specific brain reorganization (Cohen & Lee, 2015) . Currently available treatment options for managing OA pain are limited, with nonsteroidal anti-inflammatory drugs being the most commonly used option. Yet NSAIDs provide only modest pain relief, and carry health risks with long-term use (Malfait & Schnitzer, 2013) . More recently, duloxetine-a centrally acting serotonin norepinephrine reuptake inhibitor-has been approved as an alternative means for treating OA pain. Multiple large multicenter RCTs in patients with knee OA, and meta-analysis of such studies, show that daily duloxetine (60/ 120 mg) in comparison to placebo results in a greater reduction in pain, improved function, and a patient-rated impression of improvement after 10-13 weeks of treatment (Chappell et al., 2009; Wang et al., 2015 Wang et al., , 2016 . Managing OA pain with centrally acting drugs is consistent with evidence demonstrating central abnormalities associated with OA (Baliki et al., 2008; Baliki, Schnitzer, Bauer, & Apkarian, 2011; Baliki, Mansour, Baria, & Apkarian, 2014; Gwilym, Filippini, Douaud, Carr, & Tracey, 2009; Hiramatsu et al., 2014; Parks et al., 2011) . These are similar to functional and anatomical brain abnormalities now associated with most chronic pain conditions (Farmer, Baliki, & Apkarian, 2012) . At least some of these anatomical changes seem to reverse over the span of months after the pain has resolved or substantially diminished (Gwilym et al., 2010; Obermann et al., 2009; Rodriguez-Raecke, Niemeier, Ihle, Ruether, & May, 2009; Seminowicz et al., 2011) . Thus, drug treatments superior to placebo should also be associated with brain anatomical renormalization, and this is the primary hypothesis of the current study. The relationship between functional and structural changes in chronic pain remains less clear. However, during the transition to chronic pain, brain regions that undergo decreased regional gray matter density (GMD) also exhibit concomitant functional connectivity changes . Thus, our secondary hypothesis is that successful drug therapy should also be accompanied with functional connectivity changes. The respective relationships between functional and anatomical reorganization, and the extent to which each or both can explain observed pain relief, remains unknown and is the primary aim of this study.
To address these hypotheses and aims, we performed a doubleblind, neuroimaging-based, placebo-controlled trial of duloxetine, and longitudinally assessed brain reorganization in patients with chronic knee OA pain after three months of treatment. Treatment-associated changes in brain structure (gray matter density) were expected to exhibit renormalization; that is, brain regions exhibiting below/above normal GMD values should tend to normal GMD values. Additionally, we assessed treatment-related functional connectivity reorganization.
Functional connectivity examines properties of information sharing in the brain. Here we studied voxel-wise functional connectivity throughout the brain by calculating local nodal degree count (DC), a measure of the number of voxels with which any given location shares information with the rest of the brain (extent of synchrony of every brain region with the rest of the brain) (Achard et al., 2012; Mansour et al., 2016) . These measures were then analyzed as a function of treatment type after we subdivided the groups into responders and nonresponders.
| M ET HOD S

| Participants
We recruited 70 individuals with chronic knee osteoarthritis pain. Of these, 31 either did not complete the trial or were removed due to technical issues with brain scans. We thus analyzed data from 39 knee OA patients (22 females; age: mean 5 58.7, SD 5 7.6 years) and also 20 age-matched control subjects (10 females; age: mean 5 57.9, SD 5 6.7 years). All OA participants were diagnosed by a clinician for knee OA, fulfilled ACR criteria, and had knee pain for at least 1 year. Another set of inclusion/exclusion criteria was imposed, including a knee pain intensity of at least 4/10 on a 11-point visual analogue scale (VAS) within 48 h of the prescreening and screening visits. All participants gave informed consent to procedures approved by the Northwestern University Institutional Review Board Committee. Subjects were recruited via newspaper or Internet advertisements in the Chicago city area and from the Northern Ohio Neuroscience, LLC clinic.
| Study design/timeline
Participants' pain and brain properties were assessed as a function of treatment, over 16 weeks and 5 visits. Brain scans were performed during the first and last visits. Visit 2 was used to assess persistence of OA knee pain, and visit 3 was used to initiate treatment (placebo or duloxetine). Drugs were prepared by an independent assistant, and all researchers interacting with participants were blinded to the administered treatment. Treatment randomization used a 1:1 allocation ratio, which was concealed until the end of the study. Patients discontinued all pain medications 2 weeks prior to beginning the treatment, and were provided with acetaminophen as rescue medication. Two duloxetine-treated and three placebo-treated patients reported worsening of knee pain; four duloxetine-treated and three placebo-treated patients reported dizziness and grogginess symptoms. No serious adverse events were reported.
We note that rs-fMRI data from the first scan of this study was used in our previous publication , where this study data set was labeled Study 2. Degree counts (DC) were extracted, for one brain region from baseline scans, to test the validity of predicting placebo propensity (details can also be found on Clinicaltrials.gov with the following accession number: NCT01558700). As shown in our previous publication , no differences in age or gender were observed between the three groups used in the current study (placebo, duloxetine, and control).
| Pain and mood parameters
All OA participants completed a general health questionnaire (PHH), the short form of the McGill Pain Questionnaire (sf-MPQ), a visual analog scale (VAS, from 0 to 10) for their knee OA pain, the Western Ontario and McMaster Osteoarthritis Index (WOMAC), the painDE-TECT questionnaire, the Beck Depression Inventory (BDI) and the Pain Catastrophizing Scale (PCS) during the course of the study. VAS was given prior to both scanning sessions and at every interim visit. All
other questionnaires (sf-MPQ, WOMAC, painDETECT, BDI, and PCS) were only administered during the scanning sessions.
| Treatment
Patients randomized to receive active treatment were given duloxetine (19 patients were randomized to this group). Treatment began at 30 mg once daily for 1 week, to allow patients to adjust to the medication before increasing to 60 mg once daily for the rest of the treatment period. For the wash-out period, patients took 30 mg once daily for 1 week before complete cessation of study drug intake. Patients randomized to receive placebo (20 patients were randomized in this group) followed the same dosing schedule, but only received pills composed of lactose.
| Scan parameters
For all participants, MPRAGE type T1-anatomical brain images were acquired with a 3T Siemens Trio whole-body scanner with echo-planar imaging (EPI) capability using a standard radio-frequency head coil with the following parameters: voxel size 1 3 1 3 1 mm; TR5 2500 ms; 
| Voxel-based morphometry
Regional gray matter density was assessed with voxel-based morphometry (VBM) using an optimized method and nonparametric statistical contrasts (Ashburner & Friston, 2000) . The FSL 5.0 software was used for brain extraction and segmentation, and FMRIB's Linear Image Registration Tool (Jenkinson, Bannister, Brady, & Smith, 2002 ) was used to spatially register the native images according to the following steps: first, a left-right symmetric study-specific gray matter template was built from the 39 gray-matter-segmented native images of OA patients. Second, custom images for each subject were generated by applying affine and deformation parameters obtained from normalizing the gray matter images, segmented in native space, to the custom template. Third, modulation was performed by multiplying voxel values by the Jacobian determinants derived from the spatial normalization step and images were finally smoothed with isotropic Gaussian kernel (sigma 5 4, FWHM 5 9,4 mm). We refer to these maps as gray matter density (GMD) maps.
| fMRI preprocessing and data analysis
The preprocessing of time series of fMRI volumes was performed using the FMRIB Expert Analysis Tool (FEAT; Smith et al., 2004 ; www.fmrib. ox.ac.uk/fsl) and encompassed: discarding the first five volumes to allow for magnetic field stabilization; skull extraction using BET; slice time correction; motion correction; spatial smoothing using a Gaussian kernel of FWHM 5 mm; and high-pass temporal filtering (150 s). Several sources of noise, which may contribute to non-neuronal fluctuations, were removed from the data through linear regression. These included the six parameters obtained by rigid body correction of head motion, the global BOLD signal averaged over all voxels of the brain, signal from a ventricular region of interest, and signal from a region centered in the white matter. All preprocessed fMRI data were registered to standard MNI space, multiplied by a common gray matter mask generated from all subjects in the study (this step was performed to limit analyses to a common set of gray matter voxels), and subsequently downsampled to yield 2912 regional cortical and subcortical nodes (8 3 8 3 8 mm isometric voxels).
| Brain graph construction
To construct the whole-brain voxel-wise connectivity networks for each subject, we first computed the Pearson correlation coefficient (R) for all possible pairs of the 2912 cortical and subcortical voxel time series from the preprocessed rs-fMRI data. For each subject, a threshold was calculated to produce a fixed number of edges, M, to be able to compare the extracted graphs at a fixed density (Achard et al., 2012) . Each of these extracted graphs comprised of N 5 2912 nodes corresponding to the number of voxels, and M undirected edges corresponding to the significant nonzero absolute values of correlation greater than the value of the threshold. Thus, in our N 3 N correlation matrix, any correlation value greater than this threshold is set to 1, where "1" indicates a connection between two brain regions. All others are set to 0. The degree count (DC) of a brain region is then equal to the total number of connections it has to the rest of the brain. DC maps of the brain were generated by assigning DC values to their corresponding voxel locations. The chosen correlation threshold (for a given density) can influence network properties (Achard & Bullmore, 2007; Achard et al., 2012) ; thus, network behavior is typically observed over a range of connection densities (where density 5 percentage of edges with respect to the maximum number of possible edges, [(N 3 N 2 1)/2]). This normalizes the number of connections each subjects' represented brain networks. However, typical ranges for connectivity matrices of the size studied here are between 2% and 15% density, and we have previously shown this range to exhibit reliable and stable network properties . Thus, we present results at only one connection density within this range, at 10%. Brain images for all figures were created using BrainNet viewer (Xia, Wang, & He, 2013) .
| Identifying brain regions modulated by treatment and response
To identify brain anatomical and functional reorganization specifically related to type of treatment and type of response, we implemented a whole-brain voxel-wise 2-way analysis of variance (ANOVA), in FSL.
Within-subject changes in GMD and DC from baseline to treatment end (DGMD and DDC, respectively) were assessed by subtracting follow-up GMD and DC maps from their respective baseline maps. We then performed a voxel-wise statistical test following a two-factor, two-level linear contrast, to assess dependence of DGMD and DDC on treatment type (DLX-vs P-treated patients), response type (responders vs nonresponders), and the interaction of treatment and response types (to identify changes specific to treatment type and response type).
Obtained results identify significant regions of interest (ROIs).
To determine if resultant ROIs encompassed brain regions known to be abnormal in OA, or were within regions predictive of placebo and duloxetine responses, we generated maps of overlap between regions identified in our design (for both DGMD and DDC); with the difference between all 39 OA subjects at scan 1 and 20 age and gender-matched healthy controls; and with the previously published set of ROIs that identify treatment response propensity .
The two-factor, two-level contrast and the OA vs controls contrast were generated using non-parametric permutation-based inference with 5,000 random permutations followed by threshold free cluster enhancement (TFCE) correction, which accounts for multiple compari- uk/fsl/fslwiki/Randomise). ROIs were identified after thresholding maps at f > 3, p < .05, for f-statistics (for drug, response and interaction contrasts, Figure 2 ) and t > 1.96, p < .05, for t-statistics (for OA vs controls contrast, Figure 4a ,c). To identify regions that commonly change in DC and GMD, obtained maps were respectively multiplied together (drug DDC 3 drug DGMD, response DDC 3 response DGMD, and interaction DDC 3 interaction DGMD). In these cases, a threshold of f > 9 was used to only display regions reaching statistical level for both GMD and DC differences.
| Mediation analysis
We performed a bootstrapped mediation analysis to evaluate potential interactions between changes in GMD and DC related to duloxetine or placebo analgesic outcome. The PROCESS macro (www.processmacro. org, version 2.16.3) in SPSS (IBM, version 20.0.0) was used with 5000 bootstrap samples, which identifies 95% confidence intervals for model components. For placebo-receiving patients, template model 6 was used (two mediators), with VAS analgesia as the outcome, DC or a GMD region used as an independent variable, and two DC or GMD regions modeled as mediators. Serial mediation was also tested to assess the interaction between the two mediators. For duloxetinereceiving patients, template model 4 was used (one mediator), with VAS analgesia as the outcome and either GMD or DC regions used as the mediator or independent variable. As recommended, a significant mediation occurs when bootstrapped upper and lower 95% confidence intervals do not include zero.
| Additional statistical analysis
To model pain relief with brain reorganization, we used multifactor linear regression analysis, performed in SPSS. VAS or WOMAC analgesia were set as the dependent variables with either all behavioral measures collected before the beginning of the treatment or all brain parameters (independently for GMD or DC ROIs) set as independent variables. Automatic stepwise forward elimination method was then used to generate a multifactorial regression model, using a p < .05 criterion for adding variables, and a p < .1 criterion for removing a variable. In a set of brain regions, we compared for GMD or DC between the control group and OA before and after treatment, as a function of type of treatment, using 1-way ANOVA, followed by post-hoc test with Dunnett correction for multiple comparisons.
| RE S U L TS
| Knee pain relief is not dependent on treatment type
To evaluate efficacy of treatment, we averaged pain intensity reports of all time points before the beginning of the treatment (weeks 0, 2, and 3; Figure 1a ) and compared them to reports at weeks 6 and 16, as a function of treatment type (duloxetine, placebo) and time ( Figure 1b ). This comparison revealed a time effect. However, there was no treatment effect, and no interaction effect between time and treatment type. When dividing patients into responders (20% or more pain relief from baseline to end of treatment) and nonresponders we observe, by design, a time-by-response interaction (Figure 1c ). Based on this subdivision, participants were designated to four categories: "duloxetine 1" for duloxetine responders, "duloxetine 2" for duloxetine nonresponders, "placebo 1" for placebo responders, and "placebo 2" for placebo nonresponders (Figure 1d ). We also assessed knee pain status via WOMAC score, since this evaluates pain, stiffness, and physical function and is known to be specific to osteoarthritis pathology, its progression in time, and in response to treatment (Gandek, 2015) .
WOMAC, similar to VAS, showed only a time effect and did not differentiate between treatments (Figure 1e ). Using the VAS-based categorization, we observe that only the responder group had a reduction in WOMAC scores (Figure 1f ).
| Brain anatomical and functional connectivity reorganization as a function of treatment type, response type, and their interaction
To determine treatment and response-dependent reorganization of brain anatomy and function, we performed a whole-brain voxel-wise 2-way ANOVA on DGMD and DDC maps (within-subject changes in GMD and DC from baseline to treatment end) (Figure 2 ). We found significant treatment type (duloxetine vs placebo) dependent changes in DC which were localized to left frontal pole, inferior temporal gyrus, precuneus cortex, and right superior parietal lobule; while GMD changes were localized to right anterior cingulate, left pre-and postcentral gyri, inferior frontal gyrus, and lateral occipital cortex (Figure 2 , top row). These were independent of response type. On the other hand, response-type-dependent, but treatment-type-independent, DC changes were observed in the right frontal and temporal poles, as well Table S4 for DC and Supporting Information, Table S5 for GMD). Thus, these data demonstrate brain region specific anatomical and functional changes that accompany the RCT, dependent on type of treatment received, on type of response to the treatments, and also more particularly on the interaction between treatment and response types. In subsequent analyses, we examine the properties of these brain regions, emphasizing their relationships to pain relief. Combining DGMD and DDC together improved the total explained variance for DVAS to 85% (Table 3 , first line), but only for the placebo group. When the behavioral measure that could explain DVAS by itself, PCS score, was added to the brain-based models (Table 3) , the total explained variance was not improved, and only the brain parameters remained significant in the model. The latter implies that the PCS properties are captured in the brain-based models in Table 3. A similar analysis was performed for the WOMAC score, which incorporates not only pain parameters, but also various quality of life proxies such as stiffness of the affected joint and physical function. We found that DGMD in the left superior parietal lobule (identified from the response contrast, Figure 2b , middle row) was able to explain DWOMAC outcome (29% variance explained) for the placebo treatment (Supporting Information, Table S1 , first line), while changes in the left precentral gyrus (same region as for DVAS outcome, identified from the response contrast, Figure 2b , middle row) explained 27% of the DWOMAC outcome for duloxetine treatment (Supporting Information, Table S1 , second line). Changes in DC in the right superior frontal gyrus (same region as for DVAS outcome, identified from the response contrast, Figure 2a , middle row) were related to DWOMAC for placebo, with 42% of the variance explained. DDC could not explain DWOMAC outcome in the duloxetine group (Supporting Information, Table S2 , first and second line respectively). Combining DGMD and DDC together did not improve the total variance explained for DWOMAC outcomes. (Figure 3) . Interestingly, there were no remarkable group differences in these 4 ROIs, although all regions showed significant correlation between either DGMD or DDC with DVAS. Thus, we observe within-subject reorganization of GMD or DC, in relation to changes in pain, although the group average structural and functional regional properties remain mostly invariant. Furthermore, no difference was observed between the magnitude of GMD changes induced by duloxe- for placebo), suggesting that a placebo was able to induce as much change in the brain as an active pharmacological treatment. Note. Abbreviations: GMD 5 gray matter density; L 5 left hemisphere; TOFC 5 temporal occipital fusiform cortex.
| Within-subject structural and functional reorganization
Results are based on stepwise multiple-regression using the 13 ROIs identified from contrast maps in Figure 2b . Values represent beta coefficients and p values in parentheses. Numbers in parentheses (under ROI names) are x, y, z coordinates (mm) of the ROI in MNI space. Note. Abbreviations: GMD 5 gray matter density; DC 5 degree counts; L 5 left hemisphere; R 5 right hemisphere; SFG 5 superior frontal gyrus; TOFC 5 temporal occipital fusiform cortex.
Results are based on stepwise multiple-regression using the best ROIs identified in Tables 1 and 2 (for DC and GMD respectively). Values represent beta coefficients and p values in parentheses. Numbers in parentheses (under ROI names) are x, y, z coordinates (mm) of the ROI in MNI space.
FIG URE 3
Patterns of reorganization for best predictors of placebo and duloxetine analgesia. ROIs with the highest beta coefficients (from models in Tables 1 and 2) are presented for the different modalities (GMD, degree count) and treatments (placebo, duloxetine). Withinsubject changes track analgesia (right panels correlation, hashed line is the threshold segregating responders and nonresponders), yet across-subject group averages (scatter graphs: individual values and mean and standard deviation for responders, red, 1, and nonresponders, blue, 2, and before, S1, and after, S2, treatment; greens are healthy controls, CTL) show minimal changes. (a) Left caudate ROI changes in GMD with placebo treatment. Across-subject group averages are not different (one-way ANOVA). However, within-subject GMD changes robustly and negatively track analgesia, where higher analgesia (responders) show proportional decrease in GMD while lower analgesia (nonresponders) show proportional increase in GMD. | 2217 names in red) were related to placebo and duloxetine analgesia respectively. When performing the same analysis for GMD differences between controls and OA patients (Figure 4c ), we also observed regions where GMD is higher in patients (yellow-red tones) or in controls (blue tones). However, none of the overlapping regions were involved in placebo or duloxetine analgesic outcome (Figure 4d ; all OAabnormal regions identified in terms of degree count and GMD are presented in Supporting Information, Table S6 ). Given that the overlap between these maps only minimally identify ROIs that significantly account for treatment (Tables 1 and 2) , we conclude that the brain reorganization following treatment is not substantially renormalizing the OA brain.
We have previously identified brain regions for which baseline DC level is predictive of placebo and duloxetine propensity ; Figure 4e ). The overlap between these regions and the brain areas shown to change during the course of treatment revealed that, in the right middle frontal gyrus (MFG) (Figure 4f , name in red), DC change was linked to duloxetine analgesia. Here too, we can conclude that treatment-related brain reorganization is minimally related with circuits predictive of placebo response.
FIG URE 4
Brain regions associated with analgesia are found in OA abnormal and treatment predictive regions. All 39 OA subjects were compared to 20 healthy age-and gender-matched controls to identify regions where OA and controls diverge for (a) degree count (DC) and (c) GMD. Delta maps obtained for DC and GMD in Figure 2 were first combined and then multiplied with respective modality to identify regions changing during the course of the treatment that overlaps with OA abnormal DC and GMD regions. Within the DC overlapping regions (b) bilateral frontal pole, that shows association with placebo and duloxetine treatment, were found in OA abnormal regions. No regions associated with placebo or duloxetine analgesia were found in abnormal regions identified in the (d) GMD overlapping map. In (e) brain regions previously identified to be predictive of placebo and duloxetine response, (f) the right middle frontal gyrus (MFG) and right parahippocampal gyrus (PHG) show overlap. However, only the MFG for duloxetine was found to be associated with analgesia [Color figure can be viewed at wileyonlinelibrary.com]
| Placebo and duloxetine engage different brain circuits to induce analgesia
We summarize the final models relating brain reorganization in association with placebo or duloxetine treatment analgesia ( Figure 5 ). Note that none of the ROIs are shared between the two treatments, even though behaviorally they induce a similar magnitude of pain relief. Table 3 [Color figure can be viewed at wileyonlinelibrary.com] to placebo, over 3 months of treatment. By generating contrasts aimed to identify brain regions changing in relation to the drug received, patient's response, and interaction of drug and response, we identified the brain regional reorganization that could explain placebo or duloxetine analgesic outcomes. We were thus able to observe unique brain functional and structural reorganization patterns linked to the active treatment and to the placebo treatment. Thus, although the two types of treatment resulted in a similar magnitude of pain relief, they were differentiated by brain sites of action, which is consistent and complimentary to our previous report showing that even prediction for placebo and duloxetine analgesia underlies distinct brain networks . In contrast, in an earlier study, we have shown that 5% lidocaine patch therapy in chronic back pain patients results in similar decrease in pain with the patch and with placebo patch, and brain activity related to both could not be distinguished from each other (Hashmi et al., 2012) , implying that mechanistically at the brain circuit level, the two treatments were the same. The current demonstration of the concept that two different treatments can lead to distinctive brain reorganization, but still induce a similar magnitude of analgesia is novel and promising for clinical applications as a tool to differentiate and validate treatment outcomes. It suggests that analgesia mechanisms for duloxetine are distinct from placebo, and that they are effective in a subset of OA patients.
Most neuroimaging studies about brain reorganization rely on a single imaging modality, where identified regions of interest are then further investigated. Our strategy was to assess changes in both structure and function, their interaction with RCT factors and resultant models for explaining pain relief; to examine the structure-function interrelationship locally and remotely (mediation analysis); and, the relative spatial proximity of these changes to brain structure and function distortions that define the OA brain, or that predict placebo analgesia in the OA brain. Studies about brain plasticity often search for GMD or functional connectivity differences as a single outcome of pathology or due to a treatment (Draganski, Kherif, & Lutti, 2014; Johansen-Berg, 2012) . Different groups are now investigating one brain modality in regard to the other one, for example, after identifying a region of GMD differences between healthy controls and the studied population, this ROI is then used as a seed for a post-hoc functional analysis (Ko et al., 2015; Kraus et al., 2014; Stoeckel, Chai, Zhang, Whitfield-Gabrieli, & Evins, 2016; Zeng et al., 2015) . This approach has the advantage of refining one of the analyses, but might neglect differences that could have been observed in the second modality. Our methodology aimed to tackle this question more comprehensively. By generating contrast maps for both structure and function, we could build regression models for pain relief, for each imaging modality, and further see if combining modalities could improve the explanation of total outcome variance.
With this approach, we showed that placebo outcome prediction can be improved when investigating changes in brain structure and function, which was not the case for duloxetine outcome. Furthermore, we assessed the contribution of pain and psychosocial parameters, at time of entry into the study to the RCT, for pain relief. Only pain catastrophizing was a predictor of RCT pain relief, and only for placebo treatment.
However, it was eliminated from the model when brain parameters were included. This observation is similar to a previous study where catastrophizing was shown to relate to the pain outcome in subacute low back pain without being an important treatment effect modifier (Smeets, Maher, Nicholas, Refshauge, & Herbert, 2009 ).
Our approach allows for direct comparison of the two types of brain changes, and to search for potential relationships. It is, however, striking that none of the six regions identified from the conjunction maps were correlated between changes in GMD and DC. Moreover, the four ROIs contributing to the models explaining RCT pain did not exhibit overall regional DC and GMD changes in comparison to healthy controls, and these ROIs were outside of brain regions that define the OA brain. These observations raise mechanistic issues regarding brain reorganization across different MRI modalities. It is fair to state that GMD and function are, to some extent, linked. By definition, neurons firing, through their coupling to cerebral blood flow, are eventually leading to the BOLD signal acquired in fMRI (Huettel, Song, & McCarthy, 2009 ). However, it is far less obvious which-change in GMD or change in brain activity-is the initial spark that further induces changes in the other brain modality. Either that continuous increase or decrease in brain activity will eventually influence GMD (namely through changes in the number of dendrites and related synapses (Kassem et al., 2013) ), or the opposite: GMD plasticity is being reflected in alteration in function after a certain time. Spatiotemporal brain reorganization is therefore a complex and may not be a unitary process. Ilg in 2008 showed that, following intensive reading practice for 2 weeks, a correlation between GMD increase and fMRI activation could be observed only in a partially overlapping brain region (Ilg et al., 2008) . We have also shown that when GMD exhibits mean changes, they are also accompanied with region DC changes ).
Here we show that after 3 months of treatment for chronic knee OA pain, no correlations could be seen in the exact locations where shared functional and structural changes were observed. But we observe within-subject reorganization of either GMD or DC in proportion to pain relief. Our mediation analysis showed that within-subject changes in DC or GMD can influence such remote regional parameters, both contributing to RCT related pain relief. Overall, we conclude that structure-function relationships for brain reorganization underlie complex and, most likely, multiple mechanisms, the details of which will require studying microscopic circuit and cellular properties/adaptations.
An important question still lingering in the field is whether brain abnormalities specific to a pain condition renormalize after a treatment, and whether this renormalization is linked to significant analgesia. Several studies have shown reversibility in structural or functional properties for various treatment approaches and pain conditions (Cummiford et al., 2016; Goswami, Anastakis, Katz, & Davis, 2016; Gwilym et al., 2010; Seminowicz et al., 2011 Seminowicz et al., , 2013 . However, none of them has investigated unbiased whole brain structural and resting state functional reorganization in relation with original difference with controls.
By comparing the differences between OA patients and controls, we
show that, of all brain regions that are changing after treatment, only two regions (left and right frontal pole) from DC reorganization actually explain analgesic outcome. This suggests that renormalization of brain properties toward control levels is possible, but that it is not a requirement to obtain efficient pain relief, at least in the context of a 3-month pharmacological treatment.
Our study shows that independent regional brain changes reflect duloxetine-and placebo-related improvement in knee OA pain. When assessing pain with VAS outcome, functional reorganization of the right superior frontal gyrus and left frontal pole, with structural reorganization of the left caudate and temporal occipital fusiform cortex were associated with placebo analgesia. Interestingly, those regions appear to be mostly different from brain regions that are associated with acute pain placebo response, which mainly involve pain-and emotional-processing brain circuitry (Amanzio, Benedetti, Porro, Palermo, & Cauda, 2013; Kong et al., 2006; Peciña, Stohler, & Zubieta, 2014; Wager & Atlas, 2015; Wager et al., 2004) .
For duloxetine analgesia, a different picture emerges, where changes in the structure of the left precentral gyrus, together with functional reorganization in the right frontal pole, explain pharmacological analgesia. This means that duloxetine analgesia involves a mixture of sensory-motor regions, relevant to the somatotopy of the knee, and more complex cognitive functional regions involved in decision-making, memory and planning . It is important to emphasize that, although our models account for a large portion of the variance of RCT pain relief, causal relationships remain unclear. It is quite likely that some regional changes are a consequence of pain relief, while others are changes due to the treatment which in turn result in pain relief. Perhaps a more temporally detailed investigation of the brain through the duration of RCT can disentangle these processes.
Yet, our models lack brain regions known to convey nociceptive information to the brain, suggesting that they may be capturing processes more involved in treatment-dependent brain reorganization, which would diminish the value attached to the incoming nociceptive input and result in pain relief (Baliki & Apkarian, 2015) .
| L I M I TA TI ONS, CONC LU SION S, A ND F U TU R E DI R EC TI ONS
The control group recruited for this study was only scanned once. Consequently, we cannot exclude the possibility that some of the shared reorganization between placebo and duloxetine are seen in regions that would normally change in a brain within the course of 3 months.
Similarly, we cannot exclude the possibility that some of the reorganization observed could represent the natural history of the disease because of the absence of a no-treatment knee OA pain group. Nevertheless, because the number of uniquely changing regions identified in the two treatments outnumbers the shared regions, we can therefore be confident that placebo and duloxetine are still inducing brain changes that would have not occurred in healthy brains or in the brains of chronic knee OA pain patients in a treatment-free situation. In this study, we used a single threshold (20%) for defining responders and nonresponders to match our previous publication , but here again we were able to show that the regions identified were tracking the continuous measure of analgesia magnitude. The mediation analysis may also be regarded as exploratory, since direct causality can only be inferred when other supporting evidence is present, or more than two time-points are collected. In conclusion, we show that, following 3 months of treatment, a placebo pill and a centrally acting drug recruit independent brain circuitry either to induce analgesia, or as a consequence of the analgesia. The specificity of gray matter density and resting state functional connectivity reorganization with duloxetine and placebo in OA remains to be validated by studying different types of chronic pain and other therapeutic approaches.
Nevertheless, our study is still the first to provide a spatial and crossmodal template leading to duloxetine and placebo pain relief. This template could help identify a patient's brain profile of response to a treatment and further help clinicians to optimize current or future treatment options to minimize patients' exposure to inefficient therapies. Moreover, we show that assessing treatment efficacy only with behavioral outcome is not optimal and could lead to false negatives, forcing the researcher to reject a treatment that may be efficient in a subset of patients through unique brain mechanisms. This study opens a window into using modern neuroimaging methods to complement the delicate task of searching for new therapies for chronic pain.
